Sobi’s years-long U.S. build-out ends in $8B go-private deal by Advent, GIC

The acceptance of an $8 billion takeout offer by Sobi’s board comes after the Swedish orphan disease company spent years growing its U.S. presence through deals, and pivoting its pipeline toward hematology and immunology.

Advent and GIC, via Agnafit Bidco AB, will pay SEK235 per share for Swedish Orphan Biovitrum AB (SSE:SOBI), representing a 35% premium over the biotech’s close of SEK174.70 on Aug. 25, before media reports of Advent’s interest in the company. The price is shy of Sobi’s SEK245 52-week high...